Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid

Kurihara, Takashi

doi:10.1016/s0002-9270(00)02013-x

Cited by 28 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…L-FABP is known as a major bile acid transporter [49,50], and the enhancement of its expression may be implicated in facilitation of intracellular bile acid mobility. Recently, the efficacy of bezafibrate has been demonstrated in patients with chronic cholestatic liver diseases, such as primary biliary cirrhosis [51][52][53]. The present results concerning L-FABP induction might partially explain the beneficial effects of bezafibrate against such diseases.…”

Section: Discussionmentioning

confidence: 54%

Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice

Nakajima

Tanaka

Sugiyama

et al. 2008

Biochemical Pharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 54%

Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice

Nakajima

Tanaka

Sugiyama

et al. 2008

Biochemical Pharmacology

View full text Add to dashboard Cite

“…74,75 New therapies are being directed at nuclear factor-jB using various activators of peroxisome proliferator-activated receptor a including the fibrates with some evidence of benefit. [76][77][78] Another potential target is nuclear receptors, and studies are currently underway with farnesoid X receptor ligands for patients with PBC. The discovery that mutations in the interleukin-12 pathway are associated with PBC 79 may lead to immunotherapy directed at this pathway.…”

Section: Future Directionsmentioning

confidence: 99%

American Association for the Study of Liver Diseases Endpoints Conference: Design and Endpoints for Clinical Trials in Primary Biliary Cirrhosis

et al. 2010

View full text Add to dashboard Cite

PreambleA group of multidisciplinary experts on primary biliary cirrhosis (PBC) and its complications convened on May 31, 2009, under the aegis of the American Association for the Study of Liver Diseases (AASLD) in order to identify the most appropriate design and endpoints for clinical trials of PBC based on current evidence and expert experience. The natural history of PBC was reviewed as well as current therapies. The current approaches to evaluating therapies for disease progression and symptoms as priorities were discussed. Appropriate aspects of trial design including entry criteria, study duration, and appropriate handling of issues such as stratification of subjects and use of ursodeoxycholic acid (UDCA), were identified and discussed. After a full day of presentations, in a consensus manner, appropriate endpoints for clinical efficacy trials regarding PBC and its complications were agreed upon and are reported in this summary.

show abstract

“…Additionally, it was recently reported that bezafibrate, a hypolipidemic agent, is effective in primary Y. Hirano,et al page 4 biliary cirrhosis treatment (Iwasaki et al, 1999;Nakai et al, 2000;Kurihara et al, 2000). In their reports, bezafibrate is more profitable than ursodeoxycholic acid in patients with primary biliary cirrhosis.…”

Section: Introductionmentioning

confidence: 99%

Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-κB activation

Hirano

Fujii

et al. 2002

European Journal of Pharmacology

View full text Add to dashboard Cite

Fibrates, hypolipidemic agents, are reported to be effective in treatment of primary biliary cirrhosis. However, the mechanism involved in therapeutic benefits of fibrates in primary biliary cirrhosis remains unknown. In contrast, hepatic regulated upon activation, normal T-cell expressed and secreted (RANTES) is increased in patients with primary biliary cirrhosis and bile acids up-regulate RANTES expression in hepatocytes. The role of fibrates in bile acid-induced RANTES expression was investigated in human hepatoma cells; 100 µM of bezafibrate and fenofibrate decreased expression of chenodeoxycholic acid-induced RANTES mRNA and protein. In addition, luciferase enzyme assay using RANTES promoter-luciferase reporter plasmid revealed that 100 µM of bezafibrate and fenofibrate transcriptionally reduced chenodeoxycholic acid-induced RANTES gene expression. Moreover, bezafibrate clearly repressed DNA-binding activity of nuclear factor-B (NF-B) induced by chenodeoxycholic acid. Therefore, fibrates might be inhibitory agents of inflammatory cell migration by RANTES to the liver in patients with primary biliary cirrhosis, possibly indicating that fibrates are therapeutic agents in primary biliary cirrhosis.

show abstract

Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid

Cited by 28 publications

References 0 publications

Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice

Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice

American Association for the Study of Liver Diseases Endpoints Conference: Design and Endpoints for Clinical Trials in Primary Biliary Cirrhosis

Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-κB activation

Contact Info

Product

Resources

About